Literature DB >> 20096956

Transcriptional profile of Parkinson blood mononuclear cells with LRRK2 mutation.

Eugénie Mutez1, Lydie Larvor, Frédéric Leprêtre, Vincent Mouroux, Dorota Hamalek, Jean-Pierre Kerckaert, Jordi Pérez-Tur, Nawal Waucquier, Christel Vanbesien-Mailliot, Aurélie Duflot, David Devos, Luc Defebvre, Alexandre Kreisler, Bernard Frigard, Alain Destée, Marie-Christine Chartier-Harlin.   

Abstract

To gain insight into systemic molecular events associated with an age-related neurodegenerative disorder, we compared gene expression patterns in peripheral blood mononuclear cells (PBMCs) sampled from elderly, healthy controls and from Parkinson's disease (PD) patients carrying the most frequently found mutation of the LRRK2 gene (G2019S). A transcriptomic approach enabled us to detect differentially expressed genes and revealed perturbations of pathways known to be involved in PD-related neurodegeneration: the ubiquitin-proteasome system, the mitochondrial oxidation system, inflammation, axonal guidance, calcium signalling and apoptosis. Moreover, alterations of the MAP kinase pathway, the actin cytoskeleton, the ephrin receptor system and vesicular transport - all recently associated with the LRRK2 G2019S mutation pathogenesis - were noted. Furthermore, we acquired new evidences of dysregulation in leukocyte extravasation signalling and immune system pathways in PD. These data show that the G2019S mutation affects the entire body and highlight some of the molecular events observed in the brain. This PBMC transcriptomic approach could be used to better understand neurodegeneration in PD and decipher new pathogenetic mechanisms, even at early stages of the disease.
Copyright © 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20096956     DOI: 10.1016/j.neurobiolaging.2009.10.016

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  33 in total

1.  LRRK2 function on actin and microtubule dynamics in Parkinson disease.

Authors:  Loukia Parisiadou; Huaibin Cai
Journal:  Commun Integr Biol       Date:  2010-09

2.  G1/S Cell Cycle Checkpoint Dysfunction in Lymphoblasts from Sporadic Parkinson's Disease Patients.

Authors:  Noemí Esteras; Carolina Alquézar; Fernando Bartolomé; Ana de la Encarnación; Félix Bermejo-Pareja; José Antonio Molina; Ángeles Martín-Requero
Journal:  Mol Neurobiol       Date:  2014-09-03       Impact factor: 5.590

3.  A Parkinson's disease gene regulatory network identifies the signaling protein RGS2 as a modulator of LRRK2 activity and neuronal toxicity.

Authors:  Julien Dusonchet; Hu Li; Maria Guillily; Min Liu; Klodjan Stafa; Claudio Derada Troletti; Joon Y Boon; Shamol Saha; Liliane Glauser; Adamantios Mamais; Allison Citro; Katherine L Youmans; LiQun Liu; Bernard L Schneider; Patrick Aebischer; Zhenyu Yue; Rina Bandopadhyay; Marcie A Glicksman; Darren J Moore; James J Collins; Benjamin Wolozin
Journal:  Hum Mol Genet       Date:  2014-05-02       Impact factor: 6.150

Review 4.  LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis.

Authors:  A Raquel Esteves; Russell H Swerdlow; Sandra M Cardoso
Journal:  Exp Neurol       Date:  2014-06-04       Impact factor: 5.330

Review 5.  Current status and future directions of gene expression profiling in Parkinson's disease.

Authors:  James G Greene
Journal:  Neurobiol Dis       Date:  2010-11-05       Impact factor: 5.996

6.  Low-variance RNAs identify Parkinson's disease molecular signature in blood.

Authors:  Maria D Chikina; Christophe P Gerald; Xianting Li; Yongchao Ge; Hanna Pincas; Venugopalan D Nair; Aaron K Wong; Arjun Krishnan; Olga G Troyanskaya; Deborah Raymond; Rachel Saunders-Pullman; Susan B Bressman; Zhenyu Yue; Stuart C Sealfon
Journal:  Mov Disord       Date:  2015-03-18       Impact factor: 10.338

7.  Analysis of blood-based gene expression in idiopathic Parkinson disease.

Authors:  Ron Shamir; Christine Klein; David Amar; Eva-Juliane Vollstedt; Michael Bonin; Marija Usenovic; Yvette C Wong; Ales Maver; Sven Poths; Hershel Safer; Jean-Christophe Corvol; Suzanne Lesage; Ofer Lavi; Günther Deuschl; Gregor Kuhlenbaeumer; Heike Pawlack; Igor Ulitsky; Meike Kasten; Olaf Riess; Alexis Brice; Borut Peterlin; Dimitri Krainc
Journal:  Neurology       Date:  2017-09-15       Impact factor: 9.910

8.  Monoclonal antibodies to discriminate the EF hand containing calcium binding adaptor proteins EFhd1 and EFhd2.

Authors:  Sebastian Brachs; Christiane Lang; Rolf Buslei; Pavitra Purohit; Barbara Fürnrohr; Hubert Kalbacher; Hans-Martin Jäck; Dirk Mielenz
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2013-08

9.  Considerations regarding the etiology and future treatment of autosomal recessive versus idiopathic Parkinson disease.

Authors:  Tohru Kitada; Julianna J Tomlinson; Hei Sio Ao; David A Grimes; Michael G Schlossmacher
Journal:  Curr Treat Options Neurol       Date:  2012-06       Impact factor: 3.598

10.  Gene expression profiling predicts pathways and genes associated with Parkinson's disease.

Authors:  Shuang Liu; Yong Zhang; Hong Bian; Xiaohong Li
Journal:  Neurol Sci       Date:  2015-08-13       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.